多发性骨髓瘤的最小残留疾病适应疗法:当前证据和意见
Mina Meseha1, James Hoffman1, Dickran Kazandjian1
1Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, 1120 NW 14th Street, Clinical Research Building, Miami, FL, 33136, USA.
Current oncology reports
|April 27, 2024
概括
最小残留疾病 (MRD) 评估为多发性骨髓瘤提供了强有力的预后见解,可能引导个性化治疗. 虽然其在适应疗法中的使用受到争论,但MRD是未来MM治疗策略的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 多发性骨髓瘤 (MM) 呈现出显著的生物异质性.
- 目前的MM治疗模式相对统一.
- 最小残留疾病 (MRD) 的评估正在成为一个关键的工具.
研究的目的:
- 评估MRD评估在MM的响应适应治疗中的作用.
- 根据MRD状态来个性化MM治疗策略.
- 审查MRD在MM管理中的当前环境和未来影响.
主要方法:
- 审查现有的MRD适应的临床试验设计 (诱导,巩固,维护).
- 对最近有影响力的研究和对MRD的回顾性数据的分析.
- 检查纵向MRD评估和正在进行的试验.
主要成果:
- MRD提供了优于传统IMWG响应标准的预后信息.
- 基于MRD的治疗调节仍然是一个有争议的话题.
- 随着时间的推移,MRD提供了对疾病治疗相互作用的见解.
结论:
- 虽然MRD是一种强大的患者级别替代品,但目前对个性化MM治疗的应用有限.
- 在不同阶段,MRD有望显著影响MM治疗策略.
- 需要进一步的研究和临床试验,才能将MRD完全整合到MM治疗决策中.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.1K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Bone Marrow Sampling and Transplants
326
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
326
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
